Výsledky vyhledávání - Mahrukh Huseni

  • Zobrazuji výsledky 1 - 16 z 16
Upřesnit hledání
  1. 1
    CD8+ T cell infiltration in breast and colon cancer: A histologic and statistical analysis

    CD8+ T cell infiltration in breast and colon cancer: A histologic and statistical analysis Autor James Ziai, Houston Gilbert, Oded Foreman, Jeffrey Eastham‐Anderson, Felix Chu, Mahrukh Huseni, Jeongmin Kim

    Vydáno 2018
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  2. 2
    The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function

    The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function Autor Robert J. Johnston, Laëtitia Comps‐Agrar, Jason A. Hackney, Xin Yu, Mahrukh Huseni, Yagai Yang, Summer Park, Vincent Javinal, Henry Chiu, Bryan Irving, Dan Eaton, Jane L. Grogan

    Vydáno 2014
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Histopathology based AI model predicts anti-angiogenic therapy response in renal cancer clinical trial

    Histopathology based AI model predicts anti-angiogenic therapy response in renal cancer clinical trial Autor Jay Jasti, Hua Zhong, Vandana Panwar, Vipul Jarmale, Jeffrey Miyata, Deyssy Carrillo, Alana Christie, Dinesh Rakheja, Zora Modrusan, Edward E. Kadel, Niha Beig, Mahrukh Huseni, James Brugarolas, Payal Kapur, Satwik Rajaram

    Vydáno 2025
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)

    Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic ren... Autor Brian I. Rini, Mahrukh Huseni, Michael B. Atkins, David F. McDermott, T.B. Powles, Bernard Escudier, Romain Banchereau, L.-F. Liu, Ning Leng, Junjie Fan, Jennifer Doss, Sam C. Nalle, Susheela Carroll, S. Li, Christina Schiff, M. Green, Robert J. Motzer

    Vydáno 2018
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial

    Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotio... Autor Brian I. Rini, Robert J. Motzer, Thomas Powles, David F. McDermott, Bernard Escudier, Frede Donskov, Robert D. Hawkins, Sergio Bracarda, Jens Bedke, Ugo De Giorgi, Camillo Porta, Alain Ravaud, Francis Parnis, Enrique Grande, Wei Zhang, Mahrukh Huseni, Susheela Carroll, Roxana I. Sufan, Christina Schiff, Michael B. Atkins

    Vydáno 2020
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma

    Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic... Autor Robert J. Motzer, Thomas Powles, Michael B. Atkins, Bernard Escudier, David F. McDermott, B. Yа. Alekseev, Jae‐Lyun Lee, Cristina Suárez, Daniil Stroyakovskiy, Ugo De Giorgi, Frede Donskov, Begoña Mellado, Romain Banchereau, Habib Hamidi, Omara Khan, Veronica Craine, Mahrukh Huseni, Nick Flinn, Sarita Dubey, Brian I. Rini

    Vydáno 2021
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial

    Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-bli... Autor Sumanta K. Pal, Robert G. Uzzo, José A. Karam, Viraj A. Master, Frede Donskov, Cristina Suárez, Laurence Albigès, Brian I. Rini, Yoshihiko Tomita, Ariel Galapo Kann, Giuseppe Procopio, Francesco Massari, Matthew R. Zibelman, I. Antonyan, Mahrukh Huseni, Debasmita Basu, Bo Ci, William Leung, Omara Khan, Sarita Dubey, Axel Bex

    Vydáno 2022
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  8. 8
    Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade

    Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade Autor Robert J. Motzer, Romain Banchereau, Habib Hamidi, Thomas Powles, David F. McDermott, Michael B. Atkins, Bernard Escudier, Lifen Liu, Ning Leng, Alexander R. Abbas, Jinzhen Fan, Hartmut Koeppen, Jennifer Lin, Susheela Carroll, Kenji Hashimoto, Sanjeev Mariathasan, Marjorie Green, Darren Tayama, Priti S. Hegde, Christina Schiff, Mahrukh Huseni, Brian I. Rini

    Vydáno 2020
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  9. 9
    Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial

    Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT... Autor Sumanta K. Pal, Laurence Albigès, Piotr Tomczak, Cristina Suárez, Martin H. Voss, Guillermo de Velasco, Jad Chahoud, Anastasia Mochalova, Giuseppe Procopio, Hakim Mahammedi, Friedemann Zengerling, Chan Kim, Takahiro Osawa, Martín Ángel, Suyasha Gupta, Omara Khan, Guillaume Bergthold, Bo Liu, Melania Kalaitzidou, Mahrukh Huseni, Christian Scheffold, Thomas Powles, Toni K. Choueiri

    Vydáno 2023
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  10. 10
    CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy

    CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy Autor Joel W. Neal, Nick Pavlakis, Sang‐We Kim, Yasushi Goto, Sun Min Lim, Giannis Mountzios, Elena Fountzilas, Anastasia Mochalova, Daniel C. Christoph, Alessandra Bearz, Xavier Quantin, Ramón Palmero, Vladan Antic, Elaine W. Chun, Tirupathi Rao Edubilli, Ya‐Chen Lin, Mahrukh Huseni, Marcus Ballinger, Vilma Graupner, Dominic Curran, Piet Vervaet, Thomas Newsom-Davis

    Vydáno 2024
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  11. 11
    Molecular determinants of response to PD-L1 blockade across tumor types

    Molecular determinants of response to PD-L1 blockade across tumor types Autor Romain Banchereau, Ning Leng, Oliver A. Zill, Ethan S. Sokol, Gengbo Liu, Dean Pavlick, Sophia L. Maund, Lifen Liu, Edward E. Kadel, Nicole Baldwin, Suchit Jhunjhunwala, Dorothee Nickles, Zoe J. Assaf, Daniel Bower, Namrata S. Patil, Mark L. McCleland, David S. Shames, Luciana Molinero, Mahrukh Huseni, Shomyseh Sanjabi, Craig Cummings, Ira Mellman, Sanjeev Mariathasan, Priti S. Hegde, Thomas Powles

    Vydáno 2021
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  12. 12
    CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

    CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma Autor Eric D. Hsi, Roxanne Steinle, Balaji Balasa, Susann Szmania, Aparna Draksharapu, Benny P. Shum, Mahrukh Huseni, David B. Powers, Amulya Nanisetti, Yin Zhang, Audie Rice, Anne van Abbema, Melanie Wong, Gao Liu, Fenghuang Zhan, Myles Dillon, Shihao Chen, Susan Rhodes, Franklin Fuh, Naoya Tsurushita, S. Madan Kumar, Vladimir Vexler, John D. Shaughnessy, Bart Barlogie, Frits van Rhee, Mohamad A. Hussein, Daniel Afar, Marna Williams

    Vydáno 2008
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  13. 13
    High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade

    High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade Autor Kobe Yuen, Lifen Liu, Vinita Gupta, Shravan Madireddi, Shilpa Keerthivasan, Congfen Li, Deepali Rishipathak, Patrick Williams, Edward E. Kadel, Hartmut Koeppen, Ying‐Jiun Chen, Zora Modrušan, Jane L. Grogan, Romain Banchereau, Ning Leng, AnnChristine Thåström, Xiadong Shen, Kenji Hashimoto, Darren Tayama, Michiel S. van der Heijden, Jonathan E. Rosenberg, David F. McDermott, Thomas Powles, Priti S. Hegde, Mahrukh Huseni, Sanjeev Mariathasan

    Vydáno 2020
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  14. 14
    First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors

    First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors Autor Tae Won Kim, Howard A. Burris, Maria J. de Miguel, Michael J. Pishvaian, Yung‐Jue Bang, Michael S. Gordon, Ahmad Awada, D. Ross Camidge, F. Stephen Hodi, Grant A. McArthur, Wilson H. Miller, Andrés Cervantes, Laura Q.M. Chow, Alexander M. Lesokhin, Annemie Rutten, Mario Sznol, Deepali Rishipathak, Shang‐Chiung Chen, Eric Stefanich, Tony Pourmohamad, Maria Inêz Padula Anderson, Jeong Kim, Mahrukh Huseni, Ina Rhee, Lillian L. Siu

    Vydáno 2022
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  15. 15
    Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

    Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma Autor David F. McDermott, Mahrukh Huseni, Michael B. Atkins, Robert J. Motzer, Brian I. Rini, Bernard Escudier, Lawrence Fong, Richard W. Joseph, Sumanta K. Pal, James A. Reeves, Mario Sznol, John D. Hainsworth, W. Kimryn Rathmell, Walter M. Stadler, Thomas E. Hutson, Martin Gore, Alain Ravaud, Sergio Bracarda, Cristina Suárez, Riccardo Danielli, Viktor Gruenwald, Toni K. Choueiri, Dorothee Nickles, Suchit Jhunjhunwala, Elisabeth Piault‐Louis, Alpa Thobhani, Jiaheng Qiu, Daniel S. Chen, Priti S. Hegde, Christina Schiff, Gregg Fine, Thomas Powles

    Vydáno 2018
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  16. 16
    CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy

    CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy Autor Mahrukh Huseni, Lifen Wang, Joanna E. Klementowicz, Kobe Yuen, Beatrice Breart, Christine Orr, Lifen Liu, Yijin Li, Vinita Gupta, Congfen Li, Deepali Rishipathak, Jing Peng, Yasin Şenbabaoğlu, Zora Modrušan, Shilpa Keerthivasan, Shravan Madireddi, Ying‐Jiun Chen, Eleanor J. Fraser, Ning Leng, Habib Hamidi, Hartmut Koeppen, James Ziai, Kenji Hashimoto, Marcella Fassò, Patrick Williams, David F. McDermott, Jonathan E. Rosenberg, Thomas Powles, Leisha A. Emens, Priti S. Hegde, Ira Mellman, Shannon J. Turley, Mark S. Wilson, Sanjeev Mariathasan, Luciana Molinero, Mark Merchant, Nathaniel R. West

    Vydáno 2023
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: